Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 5,45 € (+127,08 %). Medianen er 5,45 € (+127,08 %).
| Køb |
6 |
| Behold |
0 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Anixa Biosciences: two clinical cancer programs show encouraging early data
At the H.C. Wainwright conference, Anixa Biosciences presented positive early data for its CAR‑T program in ovarian cancer (14 patients treated; one survived 28 months, several >1 year vs expected ~12 weeks) and for a breast cancer vaccine that completed phase I with 35 patients and showed immune responses in ~75%. The company has $14M in cash, an annual burn rate of $5–7M, is debt‑free, and plans to out‑license both programs to partners after clinical success rather than build a large commercial infrastructure. Next clinical steps are dose escalation for the CAR‑T and moving the vaccine into phase II with a randomized neoadjuvant design. » Mere på de.investing.com
Anixa has treated first patient in fifth cohort with highest CAR‑T dose in ovarian cancer
Anixa has treated the first patient in the fifth cohort of its Phase 1 study at Moffitt Cancer Center with 1×10^7 CAR‑positive cells/kg, the highest dose level tested to date. No dose‑limiting toxicities were observed at the previous dose level (3×10^6/kg). The Lira‑Cel therapy targets the follicle‑stimulating hormone receptor and has shown long‑term survival of up to more than two years in some patients. The stock recently rose 14.7% to $3.27, with a market capitalization of $111 million. » Mere på de.investing.com
Anixa secures patent for breast cancer vaccine in South Korea
The Korean Intellectual Property Office granted Anixa the patent (No. 10-2960889) for its breast cancer vaccine technology, providing protection in South Korea until 2040. The technology, exclusively licensed from the Cleveland Clinic, aims at prevention and treatment by immunization against human α-Lactalbumin. A phase‑1 study met all primary endpoints, was safe, well tolerated and showed an immune response in 74% of participants. Anixa remains clinically unbalanced but has more liquid assets than debt; analysts see price targets of $7–14 versus the current level of about $2.79. » Mere på de.investing.com
Anixa Biosciences receives patent in Mexico for breast cancer vaccine
The Mexican Institute of Industrial Property has granted Anixa Biosciences a patent (No. 432748) covering key aspects of its breast cancer vaccine targeting α-lactalbumin, protecting the technology in Mexico until 2040. The vaccine, licensed exclusively from the Cleveland Clinic, met primary endpoints in a phase‑1 trial, showed good tolerability and elicited immune responses in 74% of participants; a phase‑2 study is being prepared. According to its balance sheet, Anixa has more cash than debt and strong short-term liquidity; analysts set price targets between $9 and $14 versus a current share price of $3.01. » Mere på de.investing.com
Anixa presents phase‑1 data on CAR‑T therapy Lira‑Cel at ISCT meeting
Anixa announced that a presentation on the ovarian cancer therapy Lira‑Cel will be given at the annual meeting of the International Society for Cell & Gene Therapy. Cheryl Cox from the Moffitt Cancer Center will report on the study design, objectives and the current status of the ongoing phase‑1 trial (NCT05316129) in patients with recurrent ovarian cancer after at least two prior therapies. Lira‑Cel is an FSHR‑targeting CAR‑T/CER‑T therapy being developed in collaboration with the Moffitt Cancer Center; Anixa remains in the clinical stage, is not profitable, has more cash than debt, and has analyst price targets between $9 and $14. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | juli 2026 | YoY |
|---|---|---|
| Omsætning | 0 | - |
| Bruttofortjeneste | -8,67 t | - |
| Nettoresultat | -2,26 mio. | 14,28 % |
| EBITDA | -2,36 mio. | 18,90 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 82,77 mio. € |
Antal aktier | 34,76 mio. |
Højeste/laveste i 52 uger | 4,96 € - 2,11 € |
| Udbytte | Nej |
Beta | 0,60 |
P/E (PE Ratio) | -8,59 |
PEG (PEG Ratio) | 0,01 |
K/I (PB Ratio) | 6,19 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
Anixa Biosciences, Inc., et bioteknologiselskab, udvikler terapier og vacciner med fokus på kritiske, uopfyldte behov inden for onkologi og infektionssygdomme. Selskabets terapiprogrammer omfatter udviklingen af en chimær endokrin receptor T-celleteknologi, en ny form for chimær antigenreceptor T-celle (CAR-T) teknologi med fokus på behandling af æggestokkræft; samt opdagelse og udvikling af antivirale lægemiddelkandidater til behandling af COVID-19, med fokus på at hæmme visse proteinfunktioner hos virussen. Selskabets vaccineprogrammer omfatter udviklingen af en vaccine mod trippelnegativ brystkræft og en forebyggende vaccine mod æggestokkræft. Selskabet udvikler desuden immunterapi-lægemidler mod kræft. Det har en samarbejdsaftale med MolGenie GmbH om at opdage og udvikle antivirale lægemiddelkandidater mod COVID-19. Selskabet var tidligere kendt som ITUS Corporation og ændrede navn til Anixa Biosciences, Inc. i oktober 2018. Anixa Biosciences, Inc. blev stiftet i 1982 og har hovedsæde i San Jose, Californien.
| Navn | ANIXA Biosciences Inc |
| CEO | Amit Kumar |
| Hjemsted | San Jose,
ca USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 07.10.1983 |
| Medarbejdere | 4 |
Deep Dive
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | ANIX |
Frankfurt | CY71.F |
Düsseldorf | A2N6ZF.DU |
München | A2N6ZF.MU |